Pharmacological blockade of TRPM7, TRPV4 and TRPC6 channels and/or silent RNA (siRNA) driven downregulation of this channel expression may be a novel therapeutic approach for IPAH patients [37]. The gene discussed is TRPC6; the disease is idiopathic pulmonary arterial hypertension.